{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T07:57:32Z","timestamp":1794211052239,"version":"4.8.0"},"reference-count":32,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n IMPORTANCE<\/jats:title>\n Long-term survival data from clinical trials show that survival curves of patients with advanced melanoma treated with immune checkpoint inhibitors (ICIs) gradually reach a plateau, suggesting that patients have a chance of achieving long-term survival.<\/jats:p>\n <\/jats:sec>\n \n OBJECTIVE<\/jats:title>\n To investigate long-term survival in patients with advanced melanoma treated with ICIs outside clinical trials.<\/jats:p>\n <\/jats:sec>\n \n DESIGN, SETTING, AND PARTICIPANTS<\/jats:title>\n Cohort study using prospectively collected data from the nationwide Dutch Melanoma Treatment Registry, including patients in the Netherlands with advanced melanoma treated with first-line ICIs from 2012 to 2019. Data were analyzed from January to September 2023.<\/jats:p>\n <\/jats:sec>\n \n EXPOSURES<\/jats:title>\n Patients were treated with first-line ipilimumab-nivolumab, antibodies that target programmed cell death (anti\u2013PD-1), or ipilimumab.<\/jats:p>\n <\/jats:sec>\n \n MAIN OUTCOMES AND MEASURES<\/jats:title>\n Progression-free survival (PFS) and melanoma-specific survival were analyzed, and a Cox proportional hazards model was used to investigate factors associated with PFS after reaching partial response (PR) or complete response (CR).<\/jats:p>\n <\/jats:sec>\n \n RESULTS<\/jats:title>\n A total of 2490 patients treated with first-line ICIs were included (median [IQR] age, 65.0 [55.3-73.0] years; 1561 male patients [62.7%]). Most patients had an Eastern Cooperative Oncology Group Performance Status of 1 or lower (2202 patients [88.5%]) and normal lactate dehydrogenase levels (1715 patients [68.9%]). PFS for all patients was 23.4% (95% CI, 21.7%-25.2%) after 3 years and 19.7% (95% CI, 18.0%-21.4%) after 5 years. Overall survival for all patients was 44.0% (95% CI, 42.1%-46.1%) after 3 years and 35.9% (95% CI, 33.9%-38.0%) after 5 years. Patients with metastases in 3 or more organ sites had a significantly higher hazard of progression after reaching PR or CR (adjusted hazard ratio, 1.37; 95% CI, 1.11-1.69).<\/jats:p>\n <\/jats:sec>\n \n CONCLUSIONS AND RELEVANCE<\/jats:title>\n This cohort study of patients with advanced melanoma treated with ICIs in clinical practice showed that their survival reached a plateau, comparable with patients participating in clinical trials. These findings can be used in daily clinical practice to guide long-term surveillance strategies and inform both physicians and patients regarding long-term treatment outcomes.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.26641","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T11:02:53Z","timestamp":1723633373000},"page":"e2426641","source":"Crossref","is-referenced-by-count":54,"title":["Long-Term Survival in Patients With Advanced Melanoma"],"prefix":"10.1001","volume":"7","author":[{"given":"Olivier J.","family":"van Not","sequence":"first","affiliation":[{"name":"Scientific Bureau, Dutch Institute for Clinical Auditing, Leiden, the Netherlands"},{"name":"Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfons J. M.","family":"van den Eertwegh","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Amsterdam UMC, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilde","family":"Jalving","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manja","family":"Bloem","sequence":"additional","affiliation":[{"name":"Scientific Bureau, Dutch Institute for Clinical Auditing, Leiden, the Netherlands"},{"name":"Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands"},{"name":"Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John B.","family":"Haanen","sequence":"additional","affiliation":[{"name":"Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rozemarijn S.","family":"van Rijn","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Medical Center Leeuwarden, Leeuwarden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen J. B.","family":"Aarts","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franchette W. P. J.","family":"van den Berkmortel","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Zuyderland Medical Center Sittard, Sittard-Geleen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian U.","family":"Blank","sequence":"additional","affiliation":[{"name":"Department of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands"},{"name":"Department of Medical Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marye J.","family":"Boers-Sonderen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Willem","family":"de Groot J. W. B.","sequence":"additional","affiliation":[{"name":"Isala Oncology Center, Isala, Zwolle, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geke A. P.","family":"Hospers","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Kapiteijn","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Leeneman","sequence":"additional","affiliation":[{"name":"Department of Health Technology Assessment, Erasmus School of Health Policy and Management, Erasmus University Rotterdam, Rotterdam, the Netherlands"},{"name":"Erasmus Center for Health Economics Rotterdam, Erasmus University Rotterdam, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piersma","family":"D.","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Medisch Spectrum Twente, Enschede, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Stevense-den Boer","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Amphia Hospital, Breda, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid A. M.","family":"van der Veldt","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology and Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Vreugdenhil G.","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Maxima Medical Center, Eindhoven, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel W. J. M.","family":"Wouters","sequence":"additional","affiliation":[{"name":"Scientific Bureau, Dutch Institute for Clinical Auditing, Leiden, the Netherlands"},{"name":"Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands"},{"name":"Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willeke A. M.","family":"Blokx","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karijn P. M.","family":"Suijkerbuijk","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,8,14]]},"reference":[{"issue":"1","key":"zoi240826r1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1634\/theoncologist.2010-0190","article-title":"Systematic review of medical treatment in melanoma: current status and future prospects.","volume":"16","author":"Garbe","year":"2011","journal-title":"Oncologist"},{"key":"zoi240826r2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ejca.2015.09.013","article-title":"Survival of patients with advanced metastatic melanoma: the impact of novel therapies.","volume":"53","author":"Ugurel","year":"2016","journal-title":"Eur J Cancer"},{"key":"zoi240826r3","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.ejca.2020.11.028","article-title":"Survival outcomes of patients with advanced melanoma from 2013 to 2017: results of a nationwide population-based registry.","volume":"144","author":"van Zeijl","year":"2021","journal-title":"Eur J Cancer"},{"issue":"8","key":"zoi240826r4","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1097\/CJI.0000000000000334","article-title":"Real-world outcomes of first-line anti-PD-1 therapy for advanced melanoma: a nationwide population-based study.","volume":"43","author":"van Zeijl","year":"2020","journal-title":"J Immunother"},{"issue":"1","key":"zoi240826r5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/nyas.2013.1291.issue-1","article-title":"Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma.","volume":"1291","author":"Wolchok","year":"2013","journal-title":"Ann N Y Acad Sci"},{"issue":"26","key":"zoi240826r6","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma.","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi240826r7","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma.","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"issue":"9839","key":"zoi240826r8","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"issue":"5","key":"zoi240826r9","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","article-title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol"},{"issue":"17","key":"zoi240826r10","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma.","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J Clin Oncol"},{"issue":"16","key":"zoi240826r11","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma.","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi240826r12","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/annonc\/mdz011","article-title":"Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.","volume":"30","author":"Hamid","year":"2019","journal-title":"Ann Oncol"},{"issue":"33","key":"zoi240826r13","doi-asserted-by":"publisher","first-page":"3937","DOI":"10.1200\/JCO.20.00995","article-title":"Five-year outcomes with nivolumab in patients with wild-type BRAF advanced melanoma.","volume":"38","author":"Robert","year":"2020","journal-title":"J Clin Oncol"},{"issue":"2","key":"zoi240826r14","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma.","volume":"40","author":"Wolchok","year":"2022","journal-title":"J Clin Oncol"},{"issue":"16","key":"zoi240826r15","doi-asserted-by":"publisher","first-page":"9522","DOI":"10.1200\/JCO.2022.40.16_suppl.9522","article-title":"Long-term survival in advanced melanoma for patients treated with nivolumab plus ipilimumab in CheckMate 067.","volume":"40","author":"Hodi","year":"2022","journal-title":"J Clin Oncol"},{"issue":"24","key":"zoi240826r16","doi-asserted-by":"publisher","first-page":"3998","DOI":"10.1200\/JCO.22.01599","article-title":"Seven-year follow-up of the phase III KEYNOTE-006 study: pembrolizumab versus ipilimumab in advanced melanoma.","volume":"41","author":"Robert","year":"2023","journal-title":"J Clin Oncol"},{"issue":"12","key":"zoi240826r17","doi-asserted-by":"publisher","first-page":"3461","DOI":"10.1002\/ijc.v147.12","article-title":"Real-world outcomes of advanced melanoma patients not represented in phase III trials.","volume":"147","author":"van Zeijl","year":"2020","journal-title":"Int J Cancer"},{"issue":"6","key":"zoi240826r18","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1097\/CMR.0000000000000832","article-title":"Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors.","volume":"32","author":"Ismail","year":"2022","journal-title":"Melanoma Res"},{"issue":"2","key":"zoi240826r19","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1200\/JCO.21.02549","article-title":"CheckMate-067: raising the bar for the next decade in oncology.","volume":"40","author":"Weiss","year":"2022","journal-title":"J Clin Oncol"},{"key":"zoi240826r20","first-page":"1","article-title":"Follow-up van pati\u00ebnten met gemetastaseerd melanoom met een langdurige respons na immuuntherapie.","volume":"2","author":"Kapiteijn","year":"2023","journal-title":"Med Oncol"},{"key":"zoi240826r21","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ejca.2016.11.021","article-title":"Dutch melanoma treatment registry: quality assurance in the care of patients with metastatic melanoma in the Netherlands.","volume":"72","author":"Jochems","year":"2017","journal-title":"Eur J Cancer"},{"issue":"2","key":"zoi240826r22","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"6","key":"zoi240826r23","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3322\/caac.v67.6","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"zoi240826r24","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time.","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin Trials"},{"issue":"17","key":"zoi240826r25","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1200\/JCO.2017.75.6270","article-title":"Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma.","volume":"36","author":"Robert","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6","key":"zoi240826r30","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00018","article-title":"BRAF and NRAS mutation status and response to checkpoint inhibition in advanced melanoma.","volume":"6","author":"van Not","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"zoi240826r31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2217\/imt-2022-0292","article-title":"Real-world outcomes with immuno-oncology therapies in advanced melanoma: final results of the OPTIMIzE registry study.","volume":"16","author":"Kirkwood","year":"2024","journal-title":"Immunotherapy"},{"issue":"5","key":"zoi240826r32","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1097\/CJI.0000000000000468","article-title":"Real-world outcomes of ipilimumab plus nivolumab combination therapy in a nation-wide cohort of advanced melanoma patients in the Netherlands.","volume":"46","author":"van Zeijl","year":"2023","journal-title":"J Immunother"},{"key":"zoi240826r28","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3294-8","volume-title":"Modeling Survival Data: Extending the Cox Model","author":"Therneau","year":"2000"},{"key":"zoi240826r26","unstructured":"R Core Team. R: A language and environment for statistical computing. 2017. Accessed July 10, 2024. https:\/\/www.r-project.org\/"},{"key":"zoi240826r27","unstructured":"Yoshida? K, Bartel? A. Tableone: create \u201ctable 1\u201d to describe baseline characteristics with or without propensity score weights. 2020. Accessed July 10, 2024. https:\/\/rdrr.io\/cran\/tableone\/"},{"key":"zoi240826r29","unstructured":"Kassambra? A, Kosinski? M, Biecek? P, Fabian? S. Survminer: drawing survival curves using \u2019ggplot2. 2020. Accessed July 10, 2024. https:\/\/cran.r-project.org\/web\/packages\/survminer\/survminer.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2822222\/van_not_2024_oi_240826_1723563160.15669.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T11:03:01Z","timestamp":1723633381000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2822222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,14]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.26641","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,14]]}}}